Abstract
Background Neutrophil–lymphocyte Ratio (NLR) is a biomarker of inflammation and was associated with diabetic retinopathy (DR) in earlier studies.
Objective To investigate the genetic loci influencing NLR and to estimate the heritability and causality of DR with the NLR polygenic risk score (PRS).
Design Genome-wide association study, conditional analysis, Fine and Gray model (FGR), Mendelian Randomization (MR)
Setting Scottish and South Indian populations drawn from population cohorts and electronic medical records.
Participants 29,317 individuals, with a considerable proportion diagnosed with diabetes.
Measurements Effect estimates from GWAS to compute PRS and causal association with DR.
Results Heritability estimates for the Scottish and Indian cohorts were 35.3% and 8.7% respectively. The top Single Nucleotide Polymorphisms (SNPs) in the multi-ancestry analysis (n=29,317) were intergenic: rs1825819 (Chr4:T/C) (Beta=-0.05, p=2.00×10-9), rs2980871 (Chr8:A/G) (Beta=0.04, p=4.64×10-8), rs2227322 (Chr17:C/G) (Beta=0.07, p=4.12×10-20) and rs4808047 (Chr19:T/C) (Beta= - 0.07, p=5.93×10-12). For the construction of best-fit PRS, we used 74,377 of 55,333,12 variants. There was a dose-response relationship between the PRS and NLR. The subhazard ratio (sHR) for NLR PRS association with DR was not statistically significant sHR=1.01 (95% CI: 0.97, 1.06, p=0.48). Null associations were observed in both cross-sectional and time-based MR analyses for PRS with DR.
Limitations A substantial proportion of the dataset was used for training the PRS algorithm. Due to trans-ancestry differences, PRS and subsequent analysis were conducted only in the Scottish cohorts.
Conclusions Multiple novel intergenic SNP associations were discovered, complementing those previously identified. Of these, some SNPs were also associated with genes known to regulate white blood cells, but not specifically NLR. More studies are required to confirm the causality between systemic inflammation and DR.
Primary Funding Source National Institute for Health Research, Pioneer and Leading Goose R&D Program of Zhejiang 2023, and the Ningbo International Collaboration Program 2023.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institute for Health Research, Pioneer and Leading Goose R&D Program of Zhejiang 2023, and the Ningbo International Collaboration Program 2023.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Tayside, Scotland UK: Ethical approval for the study was provided by the Tayside Medical Ethics Committee (REF:053/04) and the study has been carried out in accordance with the Declaration of Helsinki. SHARE, Scotland UK: Ethical approval of the study was provided by the ethics committee SHARE East of Scotland (REF: NHS REC 13/ES/0020). DMDSC: NIHR Global Health Research Unit on Global Diabetes Outcomes Research, Institutional Ethics Committee of Madras Diabetes Research Foundation, Chennai, India. IRB number IRB00002640. Granted 24th August 2017.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- BMI
- Body Mass Index
- CI
- Confidence Interval
- CIF
- Cumulative Incidence Function
- chr: Position
- Chromosome to Position
- CURES
- Chennai Urban Rural Epidemiology Study
- DBP
- Diastolic Blood Pressure
- DMDSC
- Dr. Mohan’s Diabetes Specialties Clinics
- DR
- Diabetic Retinopathy
- eGFR
- Estimated Glomerular Filtration Rate
- FE
- Fixed Effects
- FGR
- Fine and Gray model
- FUMA
- Functional Mapping aand Annotation of Genome-wide Association Studies
- GCTA
- Genome-wide Complex Trait Analysis
- GIF
- Genomic Inflation Factor
- GoDARTS
- Genetics of Diabetes Audit and Research in Tayside Scotland
- HbA1c
- Glycated Haemoglobin
- HDLc
- High-density lipoprotein cholesterol
- HIC
- Health Informatics Centre
- HRC
- Haplotype Reference Consortium
- HWE
- Hardy-Weinberg Equilibrium
- LD
- Linkage Disequillibrium
- LDL-C
- Low-density Lipoprotein -Cholesterol
- MAGMA
- Multi-marker Analysis of GenoMic Annotation
- MDRF
- Madras Diabetes Research Foundation
- NLR
- Neutrophil Lymphocyte Ratio
- Non-HDL-C
- Non–high-density Lipoprotein Cholesterol
- PLR
- Platelet-lymphocyte ratio
- PRS
- Polygenic Risk Score
- RET
- Receptor Tyrosine Kinase
- SBP
- Systolic Blood Pressure
- SD
- Standard Deviation
- SHARE
- Scottish Health Research Register
- SE
- Standard Error
- sHR
- Sub Hazard Ratio
- SNP
- Single Nucleotide Polymorphisms
